Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Substrate of
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Alfuzosin, Xatral; Belgium: Alfuzosine, Xatral; Bulgaria: Xatral; Cyprus: Xatral; Czech Republic: Alfuzosin, Alfuzostad, Xatral; Denmark: Alfuzosin, Benestan, Prostazosin, Xatral; Estonia: Alfuzosin, Xatral; Finland: Alfuzosin, Lafunomyl, Xatral; France: Alfuzosine, Urion, Xatral; Germany: Alfunar, Alfusin, Alfuzosin, Prostalfin Retard, Urion, Xatral; Greece: Alcinin, Alfural, Alfuzin, Alfuzosin, Alfuzosine, Ofuxal, Rilif, Xatral, Zoprost; Hungary: Alfetim, Alfugen, Alfuzosin, Alfuzostad, Fetamozin; Ireland: Alfirum XL, Alfu, Tevax, Xatral; Italy: Alfuzosina, Mittoval, Xatral; Latvia: Alfuzosin; Lithuania: Alfuzosin; Luxembourg: Xatral; Malta: Xatral; Netherlands: Alfuzosine, Xatral; Poland: Alfuzosin, AlfuZostad, Alreos, Alugen, Cezin, Dalfaz, Kofuzin; Portugal: Alfuzosina, Benestan; Romania: Alfuran, Xatral; Slovakia: Alfuzosin, Alfuzostad, Xatral; Spain: Alfuzosina, Benestán, Unibenestán; Sweden: Alfuro, Alfuzosin, Lafunomyl, Plifusil, Urozosin-Hexal, Xatral; UK: Alfuzosin, Besavar XL, Xatral.

North America

Canada: Alfuzosin, Xatral; USA: Alfuzosin, Uroxatral.

Latin America

Argentina: Dalfaz, Uroxatral; Brazil: Xatral; Mexico: Ranplasia OD, Xatral.

Drug combinations


Alfuzosin Hydrochloride: C~19~H~27~N~5~O~4~ HCl. Mw: 425.91. (1) 2-Furancarboxamide, (±)-N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-, monohydrochloride; (2)(±)-N-[3-[(4-Amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furamide monohydrochloride. CAS-81403-68-1; CAS-81403-80-7 (alfuzosin)(1984).

Pharmacologic Category

Sympatholytic (Adrenergic Blocking) Agents; Selective α-Adrenergic Blocking Agents; Quinazoline Derivatives. (ATC-Code: G04CA01).

Mechanism of action

Antagonist of α~1~-adrenoreceptors in the lower urinary tract. Blocks α~1~-adrenoreceptors, causing smooth muscles in the bladder neck and prostate to relax, thus improving urine flow rate and reducing symptoms of benign prostatic hyperplasia.

Therapeutic use

Treatment of the functional symptoms of benign prostatic hyperplasia (BPH).

Pregnancy and lactiation implications

Not indicated for use in women.

Unlabeled use


Hypersensitivity to alfuzosin or any component of the formulation. Hepatic impairment. Concurrent use with potent CYP3A4 inhibitors (e.g. itraconazole, ketoconazole, ritonavir).

Warnings and precautions

Discontinue if symptoms of angina occur or worsen. Intraoperative floppy iris syndrome has occurred with cataract surgery. Might cause orthostatic hypotension and syncope. Caution in hepatic (contraindicated if moderate or severe) or renal impairment. Might prolong QT interval (use with caution in patients with known QT prolongation (congenital or acquired)). Not intended for use as an antihypertensive. Not for use in children.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart